Science Independently confirmed 2 publishers 3 min read Published Sep 2, 2026, 7:59 AM PDT

Specialty societies take over the seasonal vaccine guidance the CDC used to co-sign

With the reconstituted ACIP tied up in court, groups speaking for pediatricians, family physicians and obstetricians reviewed the flu, Covid and RSV evidence themselves, and landed close to where the old federal process did.

The Scientist · Science desk

Send a correction

Illustration accompanying Specialty societies take over the seasonal vaccine guidance the CDC used to co-sign — Generated illustration

What happened

Organizations representing pediatricians, family physicians and obstetricians released joint guidance Wednesday, with the University of Minnesota's Vaccine Integrity Project, on who should get influenza, Covid-19 and RSV vaccines this winter.
Guidance of this kind used to be issued in liaison with the Centers for Disease Control and Prevention, and that collaborative process has broken down, leaving the societies publishing on their own.
The CDC's Advisory Committee on Immunization Practices was fired in June 2025 by health secretary Robert F. Kennedy Jr. and largely replaced with vaccine skeptics.
A court challenge to that restructuring has left both the reconstituted ACIP and the recommendations it issued in legal limbo.
The reasoning behind each recommendation was published Wednesday in the Journal of the American Medical Association, along with an interactive tool for clinicians and the public to inspect the underlying science.

Why it matters

Who has to decide decision Clinics and health systems have to settle before the season which document their protocols cite, because the societies' recommendations and the reconstituted ACIP's are now separate texts with separate standing.
What it limits constraint A once-per-lifetime adult RSV dose caps what maternal immunization can do across a reproductive career, so second and third pregnancies shift protection onto a product given to the newborn instead of the mother.
Who's exposed exposure Missing or ambiguous maternal vaccination records now decide which intervention a baby receives, which turns record quality into a bedside clinical trigger rather than an administrative annoyance.
What it sets up precedent Publishing the rationale in a journal gives this non-federal channel a citable paper trail that can be maintained, and pointed to in disputes, whichever way the litigation over ACIP goes.

Next story · Leadership · yesterday

HHS sends the White House a peptide access policy for specialty pharmacies

Confirmed2 publishers

The informative part of the release is how little of it changed. Each society ran its own review of the evidence for the seasonal respiratory vaccines, with support from the Vaccine Integrity Project, which sits inside the University of Minnesota's Center for Infectious Disease Research and Policy ^[4], and the resulting recommendations largely track what the CDC-liaised process produced before the upheaval ^[5]. The reviewers changed while the evidence stayed the same, and the output barely moved. That is the closest thing to a control this situation allows, and it is a weak one, because a single organisation supported all of the reviews ^[15]. This reads less like independent replication than one careful reading of the literature with several signatures attached.

The substantive change is obstetric. ACOG stretched the window for maternal RSV vaccination, which previously ran Sept. 1 to Jan. 31, out to March 1 ^[9], on chief medical officer Christina Davidson's account that recent RSV seasons have started later and run longer than what was previously seen ^[10]. Counted on a non-leap calendar, that is 153 days becoming 182, twenty-nine extra days, about 19 percent more window ^[16]. The announcement offers no surveillance behind "later and longer": no onset dates, no count of seasons compared, no magnitude. A timing rule justified by seasonal drift is only as sound as the drift estimate, and this one is asserted rather than shown.

The RSV product logic is where the guidance gets operationally awkward. The adult vaccine remains a single lifetime dose, because it is still unclear when or how often adults should be boosted ^[11], so a patient can be immunised during one pregnancy only. In later pregnancies the protection moves to the infant, in the form of monoclonal antibodies for babies 8 months or younger going into a first RSV season ^[12]. The American Academy of Pediatrics applies that same route to babies whose mothers were not vaccinated or whose status is unclear, and to high-risk children entering a second season ^[13].

Timing carries weight on the influenza side too: Sarah Nosal, president of the American Academy of Family Physicians, notes that the effect of flu vaccination wanes across a season, which makes October the better month ^[14]. This guidance is silent on who pays. Nothing in the announcement addresses coverage or reimbursement for the vaccines it recommends ^[17], and a recommendation a clinician endorses but a payer declines is a different object in a clinic than one both accept. Bruce Gellin, of the project's board of advisers, framed the exercise as holding a standard rather than replacing an agency: "Whatever happens to the federal vaccine policy process, we cannot lower that scientific standard" ^[7].

What to watch

The outcome of the court challenge to the ACIP restructuring, which would either revive or void the recommendations the new panel made.
Whether the March 1 maternal RSV window is picked up by other societies, and whether the surveillance data behind 'later and longer' seasons is published.
Whether the JAMA rationale papers and the interactive tool get revised mid-season if RSV onset shifts again.

Clarity's read

What the record supports and how the coverage leans. The claims behind it follow.

Reality

Evidence72
Adoption42
Hype gap−12
Incentives65
Confidence66

Why these scores

Claim ledger

Ranked by verification strength, evidence, and original report placement.

[1]
Professional organizations representing pediatricians, family physicians, obstetricians and other medical professionals jointly released guidelines on Wednesday for who should get vaccines against influenza, Covid-19 and respiratory syncytial virus (RSV) this coming winter, in conjunction with the University of Minnesota's Vaccine Integrity Project.
Reported Supported
[2]
In previous years these organizations liaised with the Centers for Disease Control and Prevention to jointly issue such guidance, and that collaborative process has broken down.
Reported Supported
[3]
The CDC's Advisory Committee on Immunization Practices was fired in June 2025 by health secretary Robert F. Kennedy Jr., a longtime vaccine critic, and largely replaced with vaccine skeptics.
Reported Supported
[4]
Each professional group reviewed the evidence for use of the seasonal respiratory vaccines with help from the Vaccine Integrity Project, which works under the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP).
Reported Supported
[5]
The renewed recommendations largely hew to previous ones from before the upheaval that has resulted in the second Trump administration.
Reported Supported
[6]
Papers outlining the rationale for the various vaccination recommendations were published Wednesday in the Journal of the American Medical Association, alongside an interactive tool to help doctors and the public review the science behind the decisions.
Reported Supported
[7]
Bruce Gellin, of the Vaccine Integrity Project's board of advisers, said at a joint press conference that Americans should have access to the best available scientific evidence and recommendations from the physicians who care for them, adding: "Whatever happens to the federal vaccine policy process, we cannot lower that scientific standard."
Reported Supported
[8]
A court challenge of that restructuring has left the ACIP and the recommendations made by the new version of it in legal limbo.
Reported Supported
[9]
The American College of Obstetricians and Gynecologists extended the period during which pregnant people can receive an RSV vaccine; previously it ran from Sept. 1 to Jan. 31 of the following year, and it now extends to March 1.
Reported Supported
[10]
Christina Davidson, ACOG's chief medical officer, said the window was extended because recent RSV seasons have started later and run longer than what was previously seen.
Reported Supported
[11]
The RSV shot for adults, pregnant or otherwise, remains a once-only vaccine because it is still not clear when or how often adults who have received it should be boosted, so pregnant people can get the vaccine in only a single pregnancy.
Reported Supported
[12]
In future pregnancies, babies will be recommended to receive RSV monoclonal antibodies if they are 8 months of age or younger going into their first RSV season.
Reported Supported
[13]
American Academy of Pediatrics recommendations say all babies 8 months and younger going into their first RSV season whose mothers did not receive the RSV vaccine during pregnancy, or whose vaccination status is unclear, should receive monoclonal antibodies, as should children going into a second RSV season who are at high risk of serious illness.
Reported Supported
[14]
Sarah Nosal, president of the American Academy of Family Physicians, noted that because the effect of flu vaccination can wane over the course of the season, the best time to get an influenza shot would be in October.
Reported Supported
[15]
Because one organisation, the Vaccine Integrity Project, supported all of the societies' evidence reviews, those reviews were not fully independent of one another.
Derived Supported
[16]
Extending the maternal RSV vaccination window from Jan. 31 to March 1 lengthens it from 153 days to 182 days, an increase of 29 days or about 19 percent, assuming a non-leap February.
Derived Supported
[17]
The reported account of the joint release does not address insurance coverage, reimbursement or payment for the vaccines it recommends.
Derived Contested

Sources

2 independent publishers whose own reporting we read for this story.

scientificamerican.com
1 article · September 2, 2026
Top medical leaders urge Americans to get their flu and COVID shots in lieu of CDC vaccine campaign
statnews.com
1 article · September 2, 2026
Doctors groups release vaccination guidelines ahead of respiratory illness season

Clarity analysis

How the coverage leans and what the record actually supports. Read the methodology

Perspective Coverage

How much of the coverage speaks to builders, operators and investors. It measures emphasis, not whether the story is right.

Builder

If you are updating a practice's standing orders or a decision-support rule this month, only STAT gives you anything to change: the RSV window in pregnancy now runs to March 1 rather than Jan. 31, the adult RSV shot stays a single lifetime dose, infants 8 months and under whose mothers were not vaccinated get monoclonal antibodies, and flu shots land best in October. Scientific American's readers get the effect sizes instead — 53 percent fewer Covid hospitalizations in adults over 65, up to 83 percent fewer RSV hospitalizations over 60 — but not a single date. The buildable artifact in this story is the interactive tool promised on the Vaccine Integrity Project's site, and neither outlet has seen it yet.

Operator

The operational fact underneath this story is that nobody is sure what these recommendations bind. The professional societies used to co-sign with the CDC; that process is broken, the reconstituted advisory committee is tied up in court, and as Scientific American reports the CDC has not launched its usual autumn campaign and did not answer a request for comment. Practices still have to order doses, and the AAP's own president says on the record that he cannot tell whether the Vaccines for Children program will cover them. Guidance arrived on schedule; the machinery that turns guidance into paid-for shots did not.

Investor

There is one money sentence in this entire story, and Scientific American has it: Andrew Racine saying Vaccines for Children covered every vaccine on last year's schedule and he cannot say what happens next. That is the whole procurement signal — no volumes, no pricing, no manufacturer named, nothing on commercial payer alignment with society-issued rather than federally-issued schedules. STAT's account, which is the detailed one clinically, does not touch payment at all. Anyone modelling seasonal vaccine demand is being handed clinical recommendations and asked to guess at the purchase orders.